ArticleParasitology research2013
Evaluation of protective effect of multiantigenic DNA vaccine encoding MIC3 and ROP18 antigen segments of Toxoplasma gondii in mice.
Article in Parasitology research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- A systematic review on efficiency of microneme proteins to induce protective immunity against Toxoplasma gondii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Pooled it
- HarnessingAnnals of medicine · 2026Review
- MIC13 ofJournal of parasitology research · 2025Article
- Article
- CD4Vaccines · 2023Article
- REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.The Journal of parasitology · 2021Review
- Protective Effect Against Toxoplasmosis in BALB/c Mice Vaccinated WithFrontiers in microbiology · 2019Article
- Rhoptry antigens asClinical and experimental vaccine research · 2019Review
- Recent progress in microneme-based vaccines development againstClinical and experimental vaccine research · 2018Review
- Immune Protection of Rhoptry Protein 21 (ROP21) ofFrontiers in microbiology · 2018Article
- A Gene-Based Positive Selection Detection Approach to Identify Vaccine Candidates UsingFrontiers in genetics · 2018Article
- Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice.The American journal of tropical medicine and hygiene · 2017Article
- Sixty Years (1957-2017) of Research on Toxoplasmosis in China-An Overview.Frontiers in microbiology · 2017Review
- Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii.Parasitology research · 2017Article
- Evaluation of Protective Immune Responses Induced by Recombinant TrxLp and ENO2 Proteins againstBioMed research international · 2016Article
- Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins.Parasitology research · 2015Article
- Protective immunity against acute toxoplasmosis in BALB/c mice induced by a DNA vaccine encoding Toxoplasma gondii elongation factor 1-alpha.BMC infectious diseases · 2015Article
- Research advances in microneme protein 3 of Toxoplasma gondii.Parasites & vectors · 2015Review
- Antiparasitic DNA vaccines in 21st century.Acta parasitologica · 2015Review
- Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis.Medical microbiology and immunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high incidence and severe damage caused by Toxoplasma gondii infection clearly indicates the need for the development of a vaccine. In this study, we evaluated the immune responses and protection against toxoplasmosis by immunizing ICR mice with a multiantigenic DNA vaccine. To develop the multiantigenic vaccine, two T. gondii antigens, MIC3 and ROP18, selected on the basis of previous studies were chosen. ICR mice were immunized subcutaneously with PBS, empty pcDNA3.1 vector, pMIC3, pROP18, and pROP18-MIC3, respectively. The results of lymphocyte proliferation assay, cytokine, and antibody determinations showed that mice immunized with pROP18-MIC3 elicited stronger humoral and Th1-type cellular immune responses than those immunized with single-gene plasmids, empty plasmid, or phosphate-buffered saline. After a lethal challenge with the highly virulent T. gondii RH strain, a prolonged survival time in pROP18-MIC3-immunized mice was observed in comparison to control groups. Our study indicates that the introduction of multiantigenic DNA vaccine is more powerful and efficient than single-gene vaccine, and deserves further evaluation and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.